Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Recaticimab (SHR-1209) is a humanized monoclonal antibody targeting PCSK9 to enhance the degradation of this enzyme. By binding to PCSK9, Recaticimab elevates low-density lipoprotein (LDL) receptor presence on hepatocyte surfaces, consequently lowering plasma LDL levels and aiding in blood lipid reduction. This mechanism positions Recaticimab as a promising therapeutic for hypercholesterolemia [1] [2].
説明 | Recaticimab (SHR-1209) is a humanized monoclonal antibody targeting PCSK9 to enhance the degradation of this enzyme. By binding to PCSK9, Recaticimab elevates low-density lipoprotein (LDL) receptor presence on hepatocyte surfaces, consequently lowering plasma LDL levels and aiding in blood lipid reduction. This mechanism positions Recaticimab as a promising therapeutic for hypercholesterolemia [1] [2]. |
分子量 | N/A |
CAS No. | 2361290-85-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Recaticimab 2361290-85-7 Inhibitor inhibitor inhibit